A macrophage-targeted TIMD4 Peptide-Nanoparticle attenuates colitis symptoms and monocyte recruitment in a mouse model
PLOS Biology · 2026
DOI: 10.1371/journal.pbio.3004056 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2026. Verfasst von Huimin Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Experimental Teratology of Ministry of Education, Key Laboratory of Infection Immunity and Disease Intervention of Shandong Provin…. Hauptthemen laut MEDLINE: Macrophages, Colitis, Monocytes, Nanoparticles. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Technology Program for Cell Therapy of NCTIB, Cutting Edge Development Fund of Advanced Medical Research Institute.
Abstract (Originalsprache)
Macrophages play a pivotal role in the pathogenesis of inflammatory bowel disease (IBD). T-cell immunoglobulin and mucin domain-containing molecule 4 (TIMD4) is involved in the regulation of tissue-resident macrophages. TIMD4 expression is elevated in colonic tissues from patients with ulcerative colitis (UC) and mice with dextran sulfate sodium (DSS)-induced colitis, but its role in IBD pathogenesis remains unclear. In this study, we found that Timd4 deficiency aggravated DSS-induced colitis, accompanied by increased infiltration of monocytes into the colonic tissues. Treatment with a CCR2 antagonist attenuated colonic inflammation and reduced monocyte infiltration into colonic tissues in Timd4 KO mice. Mechanistically, in vitro studies revealed that TIMD4 stabilized the LKB1-STRAD-MO25 complex via its intracellular domain, thereby activating the AMPK pathway and suppressing NF-κB-dependent chemokine production in macrophages. Based on these findings, we designed a TIMD4-derived peptide and developed a macrophage-targeted nanoparticle system (T4 (365–378) ‑NPs). Treatment with T4 (365–378) -NPs reduced P65 phosphorylation and attenuated DSS-induced colitis in mice. Treatment with either T4 (365–378) -NPs or the CCR2 antagonist attenuated DSS-induced colitis, and no statistically significant differences in the assessed outcomes were detected between the two groups. Administration of T4 (365–378) -NPs before DSS exposure also attenuated subsequent colitis. Furthermore, combining the T4 (365–378) ‑NPs with anti-α4β7 or anti-TNF-α antibodies produced greater improvements than either monotherapy in the DSS-induced colitis model. These findings support further preclinical evaluation of TIMD4-derived peptide delivery as a potential therapeutic approach for intestinal inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Experimental Teratology of Ministry of Education, Key Laboratory of Infection Immunity and Disease Intervention of Shandong Province, and Department of Immunology, School of Basic Medical Sciences, Ch…
- Department of Biomaterials, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Mat…
- The First School of Clinical Medicine, Shandong University, Jinan, Shandong, P. R. China.
- Department of Oral Medicine, Jining Medical University, Jining, Shandong, P. R. China.
- Department of Rheumatology, Fuding Hospital, Ningde City, Fujian Province, P. R. China.
- Key Laboratory for Experimental Teratology of Ministry of Education, Department of Cell Biology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P. R. China.
ORCID-Profile: Lifen Gao
Förderung
- National Natural Science Foundation of China
- Key Technology Program for Cell Therapy of NCTIB
- Cutting Edge Development Fund of Advanced Medical Research Institute
- Major Science and Technology Innovation Project of Shandong Province
- National Natural Science Foundation of China Youth Science Project
- Taishan Scholar Foundation of Shandong Province
Zitieren
APA
Liu, H., Wang, Y., Yu, R., Liu, K., Zheng, D., Wang, B., Chang, Y., Liu, B., Yue, X., Wu, Z., Li, C., Liang, X., Ma, C., Liu, G., Li, J., Xu, L., & Gao, L. (2026). A macrophage-targeted TIMD4 Peptide-Nanoparticle attenuates colitis symptoms and monocyte recruitment in a mouse model. PLOS Biology. https://doi.org/10.1371/journal.pbio.3004056
Vancouver
Liu H, Wang Y, Yu R, Liu K, Zheng D, Wang B, et al. A macrophage-targeted TIMD4 Peptide-Nanoparticle attenuates colitis symptoms and monocyte recruitment in a mouse model. PLOS Biology. 2026. doi:10.1371/journal.pbio.3004056
BibTeX
@article{Liu2026,
author = {Liu, Huimin and Wang, Yuzhen and Yu, Ruiqing and Liu, Kexin and Zheng, Dezhi and Wang, Bo and Chang, Yuan and Liu, Bing and Yue, Xuetian and Wu, Zhuanchang and Li, Chunyang and Liang, Xiaohong and Ma, Chunhong and Liu, Guohua and Li, Jianhua and Xu, Leiqi and Gao, Lifen},
title = {A macrophage-targeted TIMD4 Peptide-Nanoparticle attenuates colitis symptoms and monocyte recruitment in a mouse model},
journal = {PLOS Biology},
year = {2026},
doi = {10.1371/journal.pbio.3004056}
}
EUVIMED